Ocumetics Announces Scientific Advisory Committee to Support Advancing Clinical and Regulatory Strategy
(TheNewswire)
Calgary, Alberta – TheNewswire - February 26, 2026 -Ocumetics Technology Corp. (“Ocumetics” or the “Company”)(TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generationophthalmic technology, today announcedthe formation of a Scientific Advisory Committee(SAC) to support the Company’s advancing clinical, regulatory, andcommercialization strategy as it progresses toward late-stagedevelopment.
The SAC will provide independent, multidisciplinaryexpertise across clinical trial design, regulatory strategy, surgicalapplication, lens science, and translational research, ensuring strongclinical governance and informed decision making as Ocumetics preparesfor pivotal clinical studies and future FDA engagement. The SAC willinclude Dr Ron Krueger, MD, MSE, a globally recognizedophthalmologist, surgeon, and innovator in refractive and cataractsurgery.
Dr. Krueger brings decades of leadership in clinicalresearch, surgical innovation, and technology translation, includingextensive experience guiding ophthalmic devices through advancedclinical development. Dr. Krueger is the McGraw Professor andChairman of Ophthalmology at the University of Nebraska MedicalCenter. He was previously on staff at Cleveland Clinic LernerCollege of Medicine of Case Western Reserve University and a seniorstaff surgeon at the Cleveland Clinic Cole Eye Institute. He isinternationally recognized for his pioneering contributions to laservision correction, cataract surgery, and presbyopia treatment, and hasauthored more than 300 peer-reviewed publications, book chapters, andscientific presentations. Dr. Krueger has served as a principalinvestigator in numerous clinical trials and has advised multipleophthalmic device companies on clinical development, regulatorystrategy, and surgical adoption.
“Dr. Krueger’s scientific rigor, clinical insight,and experience translating innovation into clinical practice make himan ideal addition to our Scientific Advisory Committee,” said DeanBurns, President and CEO of Ocumetics. “As we enter a more complexphase of development, this committee structure ensures we are drawingfrom the best collective expertise to guide our clinical execution andregulatory strategy.”
The Scientific Advisory Committee will function as astrategic advisory body, providing guidance on:
Clinical trial design and endpointoptimization
First-in-human and pivotal study execution
Regulatory strategy and FDA engagement
Surgical usability and adoption considerations
Risk assessment and clinical governance
Commercialization readiness and physicianeducation
Additional members of the SAC will be announced in thecoming months. Ocumetics remains focused on advancing itsaccommodating intraocular lens technology through clinical validationand regulatory milestones, with the goal of delivering innovativevision solutions to patients worldwide.
About Ocumetics
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO)is a Canadian research and product development company that isdedicated to developing advanced vision correction solutions thatenhance the quality of life for patients. Through innovativeresearch and development, Ocumetics aims to transform the field ofophthalmology with state-of-the-art intraocular lenses and othervision-enhancing technologies.
Ocumetics is in the first-in-human early feasibilitystudy phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within thenatural lens compartment of the eye, potentially to eliminate the needfor corrective lenses. It is designed to allow the eye’s naturalmuscle activity to shift focus from distance to near, providing clearvision at all distances without the help of glasses or contact lenses.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dave Burwell
Director, Investor Relations
(403) 410-7907
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to,statements with respect to the commencement, timing and scope of theresearch and development to be conducted by the Company mentionedabove. Forward-looking statements are necessarily based upon anumber of estimates and assumptions that, while considered reasonable,are subject to known and unknown risks, uncertainties, and otherfactors which may cause the actual results and future events to differmaterially from those expressed or implied by such forward-lookingstatements. Such factors include but are not limited to: operationalmatters, historical trends, current conditions and expected futuredevelopments, access to financing as well as other considerations thatare believed to be appropriate in the circumstances. There can be noassurance that such statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, readers should not placeundue reliance on forward-looking statements. The Company disclaimsany intention or obligation to update or reviseany forward-looking statements, whether as a result of newinformation, future events or otherwise, except as required bylaw.
Copyright (c) 2026 TheNewswire - All rights reserved.
NASDAQ: OTCFF
OTCFF Trading
0.0% G/L:
$0.31 Last:
2,000 Volume:
$0.31 Open:
